TNGX · Tango Therapeutics, Inc.

Current Thesis

The binary that defined this name a year ago has resolved to the upside and the question has shifted from "will the PRMT5 data work" to "how big is the franchise." Vopimetostat (formerly TNG462), an MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers, posted Phase 1/2 monotherapy data on 2025-10-23 that the Street read as best-in-class: 27% ORR across 16 tumor types at 9.4-month median follow-up, and in second-line MTAP-deleted pancreatic cancer a 25% ORR with 7.2-month median PFS, roughly double historical control. FDA alignment on a 250 mg once-daily go-forward dose followed. The stock re-rated from a $3.12 52-week low to a $28.41 high and now trades near $20, digesting that move below its 50-day average while holding ~50% above the 200-day. The next leg is no longer monotherapy; it is the 2026 combination readout (vopimetostat + daraxonrasib and + zoldonrasib) that, per the 2026-05-13 Q1 report, may open a registrational path in first-line pancreatic cancer. With $379.8M cash funding operations into 2028 and a ~30% short float, this is a funded, de-risked clinical-momentum name in a consolidation, not a pre-data lottery ticket.

Bull Case

• Monotherapy data already de-risked the asset (2025-10-23): 27% ORR across 16 tumor types at 9.4-month median follow-up; second-line MTAP-deleted PDAC at 25% ORR / 7.2-month median PFS against ~10–11% historical control. This is published efficacy, not preclinical hope.
• Balance sheet removes the prior overhang: $379.8M cash/equivalents/marketable securities at 2026-03-31, runway guided into 2028 (Q1 report 2026-05-13). The financing-at-weakness fear that defined the small-cap version of this name is off the table; a $100M Leerink ATM (Nov 2025) sits in reserve rather than in active distribution.
• Analyst re-rating is clustered and recent (post-Q1, May 2026): Leerink $28→$55, Wedbush $19→$33, Mizuho $20→$30, Stifel $15→$24, H.C. Wainwright $13→$27; consensus ~$32, Buy. Every published target sits above the ~$20 tape the sell-side is marking the name up into the consolidation.
• ~30% short float / 9.5 days to cover is mechanical squeeze fuel layered on any positive 2026 combo print the two-legged move (fundamental re-rate plus a forced cover) is where the outsized session lives.
• FDA-aligned 250 mg QD dose plus planned 2026 combo data → potential 1L PDAC pivotal path (per 2026-05-13 guidance). Moving from 2L monotherapy into 1L combination expands the addressable franchise materially.
• M&A comp is live: BMS's $4.8B Mirati/KRAZATI take-out validated MTAP-adjacent synthetic-lethality biology at pharma-scale multiples; a clean combo dataset makes vopimetostat a credible acquisition asset.

Bear Case

• The easy money is already paid out. The $3→$28 re-rating happened on the Oct-2025 monotherapy data. A fresh buyer near $20 is paying up for combo data that is not yet on the tape and is only guided to "2026" with no firm date the move has matured.
• Piper Sandler downgraded on a "strategy shift" (2026) a genuine dissenting voice against an otherwise unanimous-bull tape; the pivot toward combination-led registration adds execution and timeline risk versus a clean monotherapy filing.
• Competition is well-funded and in places ahead: Amgen's AMG 193 remains the benchmark PRMT5i; IDEAYA/GSK's IDE397 is a third entrant on the same synthetic-lethality axis. A materially cleaner AMG 193 PDAC combo readout compresses vopimetostat's best-in-class premium.
• The value-driving combo data is binary and undated. Initial vopimetostat + daraxonrasib / + zoldonrasib safety and efficacy is the catalyst; a sub-20% ORR or a tolerability signal removes the 1L pivotal path and de-rates the multiple.
• Structure is cooling rather than accelerating: below the 50-day, RSI ~44, ~29% off the $28.41 high. An entry into a name with no near-term dated catalyst and a fading short-term trend risks dead money or a fill down toward the 200-day.
• Collaboration revenue is gone ($0 vs $5.4M as the Gilead deal wound down); burn is now fully self-funded ($45.5M Q1 net loss, $0.32/sh), so the 2028 runway depends on no negative surprises.

Setup & Price Structure

Tape near $20.22, off a $28.41 52-week high and a $3.12 low a ~7x trough-to-peak that has since corrected ~29%. Price sits ~10% below the 50-day SMA (~$22.5) but ~50% above the 200-day (~$13.3): short-term digestion inside an intact long-term uptrend. RSI ~44 is neutral, with no overbought blow-off and no oversold capitulation. Average volume runs ~3.3M; the ~30% short float (31.8M shares, 9.5 days to cover) is the dominant structural feature. The clean momentum re-entry is a reclaim of the 50-day (~$22.5–23) on above-average volume, which would simultaneously pressure the short base; absent that, the constructive zone is a higher low that holds the May breakout shelf. Buying at-market below the 50-day with no dated catalyst is the lower-quality entry. Consensus PT ~$32 with the Leerink $55 outlier frames the upside skew if the combo data lands.

Catalyst Calendar (next 30 days)

• No hard-dated company catalyst inside the 2026-06-07 → 2026-07-07 window. ASCO 2026 (late May/early June) has passed; the next major medical-meeting venue is ESMO (~October 2026, est.).
• Vopimetostat + daraxonrasib / + zoldonrasib initial Ph1/2 combo data guided "2026," undated (Q1 report 2026-05-13). Highest-variance forward event; likely 2H 2026, possibly an ESMO drop or a standalone release. Watch for an abstract-title release ahead of any conference.
• Vopimetostat monotherapy lung-cancer Ph1/2 update "2026," undated.
• TNG456 monotherapy Ph1/2 initial safety/efficacy "2026," undated.
• ERAS-0015 combination initiation guided 2H 2026.
• Q2 2026 financial results est. ~2026-08-12 (one quarter after the 2026-05-13 Q1 print), outside the 30-day window.

What Would Change Our Mind

• Combo readout disappoints: the 2026 vopimetostat + daraxonrasib/zoldonrasib data prints sub-20% ORR or a tolerability signal that removes the 1L PDAC pivotal path thesis broken irrespective of price.
• Competitor leapfrog: Amgen AMG 193 (or IDEAYA IDE397) posts a materially cleaner PDAC combo dataset, collapsing the best-in-class premium.
• Structural break: a weekly close that loses the rising 200-day region (~$13–14) ends the long-term uptrend; repeated lower highs and a failure to reclaim the 50-day (~$22.5) keep the name dead money.
• Financing surprise: activation of the Leerink ATM into weakness, or guidance that pulls the 2028 runway forward, reintroduces the dilution overhang the cash balance currently neutralizes.
• Confirmation to lean in: a 50-day reclaim on >1.5x volume that begins forcing the ~30% short base to cover, ideally into a dated combo-data window.

Correlation Notes

• Same-factor names: IDEAYA (IDE397) and Repare (RPTX) share MTAP / synthetic-lethality and PRMT5-adjacent factor risk; correlated readouts mean stacking them multiplies a single factor exposure rather than diversifying it. Amgen (AMGN, AMG 193) is the large-cap benchmark whose PDAC data reads inversely on vopimetostat's premium.
• Catalyst linkage: the combo thesis is tied to Revolution Medicines' RAS(ON) inhibitors (daraxonrasib, zoldonrasib) RVMD pancreatic data and the Tango combo move together, and an RVMD setback bleeds directly into the 1L pivotal path.
• Sector beta: as a profitless ~$2.9B clinical biotech, TNGX trades with XBI risk appetite and is rate-sensitive a risk-off small-cap-biotech tape can overwhelm single-name narrative in any given week.